Pangea Biomed is the developer of ENLIGHT, an advanced pan-cancer, pan-therapy response predictor. By combining machine learning, artificial intelligence, and deep RNA analysis, the company is mapping tumor molecular signatures to dynamically and adaptively personalize cancer care. Pangea's unsupervised machine-learning approach makes ENLIGHT scalable and effective during the drug development process, when no clinical data is yet available. Pangea is also developing EnlightDP, a response prediction technology based on the analysis of digital H&E slide images using its proprietary RNA expression imputation platform. Pangea aims to bring effective precision oncology to cancer patients, improve oncology drug development, and empower oncologists to treat patients with success. Pangea is backed by NFX, and validations of its technology have been published in leading journals, including Med, Cell, Science Advances, Cancer Cell, and Nature Communications.